ArticlePLoS computational biology2025
serojump: A Bayesian tool for inferring infection timing and antibody kinetics from longitudinal serological data.
Article in PLoS computational biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Kinetics of antibodies and risk of respiratory syncytial virus infection: a longitudinal cohort in Taizhou City, eastern China.BMC medicine · 2026Article
- serocalculator, an R package for estimating seroincidence from cross-sectional serological data.medRxiv : the preprint server for health sciences · 2025Article
Corrections and comments
- Update of
Authors and funding
7 authors.
Funding
Abstract
Understanding acute infectious disease dynamics at individual and population levels is critical for informing public health preparedness and response. Serological assays, which measure a range of biomarkers relating to humoral immunity, can provide a valuable window into immune responses generated by past infections and vaccinations. However, traditional methods for interpreting serological data, such as binary seropositivity and seroconversion thresholds, often rely on heuristics that fail to account for individual variability in antibody kinetics and timing of infection, potentially leading to biased estimates of infection rates and post-exposure immune responses. To address these limitations, we developed serojump, a novel probabilistic framework and software package that uses individual-level serological data to infer infection status, timing, and subsequent antibody kinetics. We validated serojump using simulated serological data and real-world SARS-CoV-2 datasets from The Gambia. In simulation studies, the model accurately recovered individual infection status, population-level antibody kinetics, and the relationship between biomarkers and immunity against infection, demonstrating robustness under observational noise. Benchmarking against standard serological heuristics in real-world data revealed that serojump achieves higher sensitivity in identifying infections, outperforming static threshold-based methods and precision in inferred infection timing. Application of serojump to longitudinal SARS-CoV-2 serological data taken during the Delta wave provided additional insights into i) missed infections based on sub-threshold rises in antibody level and ii) antibody responses to multiple biomarkers post-vaccination and infection. Our findings highlight the utility of serojump as a pathogen-agnostic, flexible tool for serological inference, enabling deeper insights into infection dynamics, immune responses, and correlates of protection. The open-source framework offers researchers a platform for extracting information from serological datasets, with potential applications across various infectious diseases and study designs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.